Compare Kinder Morgan Inc (KMI) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Eli Lilly And Co — how do they compare? Kinder Morgan Inc trades at $31.8 (market cap $70.10B), while Eli Lilly And Co trades at $1,222.55 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 15.4× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| KMI | LLY | |
|---|---|---|
Market Cap | $70.10B | $1.08T |
Sector | Energy | Health |
52-Week High | $34.31 | $1.24K |
52-Week Low | $25.84 | $639.43 |
Enterprise Value | $102.15B | $1.13T |
Dividend Yield | 3.75% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KMI trades at $31.76, up 1.16% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates, and raised full-year guidance. Revenue grew to $16.94B in 2025, with net income margin expanding to 19.31%. Recent news highlights a $5 billion Western Gateway Pipeline joint venture final investment decision.
Outlook is supported by robust cash flow, a $10 billion project backlog, and growing LNG demand, but risks include high debt levels and execution challenges. Analysts are mixed with 47% buy ratings. The stock offers a dividend yield near 3.7%, appealing for income-focused investors amid stable fee-based operations.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
